Fundraising FoxAmgen
NASDAQ: AMGNThousand Oaks, US · Delaware corporation · 3 known investors
Find your way into Amgen
2,160 people in our graph share verified history with the Amgen team — schools, employers, funds. One of them is your warm intro.
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Founders & leadership
Investors · 3
How we know: Asset Management Company's portfolio page · Not right? Tell us
How we know: Mayfield Fund's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements▶$2.5BofferedJan 2015 · 34 investors · BiotechnologyRule 506(b)
- David PiacquadExecutive Officer
- Francois de CarbonnelDirector
- Brian M. McNameeExecutive Officer
- Tyler JacksDirector
- Ronald D. SugarDirector
- Robert A. BradwayExecutive Officer, Director
- David J. ScottExecutive Officer
- Madhavan BalachandranExecutive Officer
- Stuart A. TrossExecutive Officer
- David W. MelineExecutive Officer
- Sean E. HarperExecutive Officer
- Rebecca M. HendersonDirector
- Judith PelhamDirector
- Vance D. CoffmanDirector
- David BaltimoreDirector
- Cynthia M. PattonExecutive Officer
- Greg C. GarlandDirector
- Frank C. HerringerDirector
- Frank J. Biondi, Jr.Director
- Robert A. EckertDirector
- Anthony C. HooperExecutive Officer
- R. Sanders WilliamsDirector
- Offering amount
- $2.5B
- Minimum investment
- $250K
- Sales commissions
- $750K
- Placement agents
- Deutsche Bank Securities Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Banc of America Securities LLC, Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated
- First sale
- Sep 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Amgen mafia →49 people who came through Amgen went on to found or lead other companies.
Acquisitions · 4
Early investors' stakes continue via these dealsAmgen is a biopharmaceutical company that develops and manufactures therapeutics targeting oncology, cardiovascular disease, inflammation, bone health, neuroscience, and other serious illnesses. The company operates globally with manufacturing facilities across the United States, Europe, and Asia, serving patients and healthcare providers worldwide.
Five Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.
Micromet was a biopharmaceutical company based in Rockville, MD and Munich, Germany that developed antibody-based cancer therapies using its proprietary BiTE (Bispecific T-cell Engager) platform, including lead candidate blinatumomab.
Nuevolution was a Copenhagen-based biopharmaceutical company developing small-molecule drugs for oncology and chronic inflammatory diseases using its proprietary DNA-encoded chemical library platform, Chemetics.
In the news
Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?finance.yahoo.com · Aug 2026
Incyte: Cheaper, Growing Faster, And The Market Keeps Paying Up For Amgen | Trefistrefis.com · Aug 2026Frequently asked questions
- What does Amgen do?
- Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
- Who are Amgen's investors?
- Amgen's investors include Asset Management Company, Mayfield Fund, Sunstone Capital.
- Where is Amgen headquartered?
- Amgen is headquartered in Thousand Oaks, US.